

Celldex Therapeutics, Inc.
 Form 3
 July 01, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Wright Richard M.		(Month/Day/Year)	Celldex Therapeutics, Inc. [CLDX]	
(Last)	(First)	(Middle)	07/01/2015	
C/O CELLDEX THERAPEUTICS, INC., Â 53 FRONTAGE ROAD, SUITE 220			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
HAMPTON, Â NJ Â 08827			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
			(give title below) (specify below)	
			Sr. VP & CCO	
			6. Individual or Joint/Group Filing(Check Applicable Line)	
			<input checked="" type="checkbox"/> Form filed by One Reporting Person	
			<input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock, par value \$0.001 per share	3,125	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: Celldex Therapeutics, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	Â (1)	06/01/2022	Common Stock	12,500	\$ 3.99	D	Â
Employee Stock Option (right to buy)	Â (2)	07/01/2023	Common Stock	20,000	\$ 16.36	D	Â
Employee Stock Option (right to buy)	Â (3)	06/04/2024	Common Stock	25,000	\$ 13.45	D	Â
Employee Stock Option (right to buy)	Â (4)	06/10/2025	Common Stock	75,000	\$ 25.41	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Wright Richard M. C/O CELLDUX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON, NJ 08827	Â	Â	Â Sr. VP & CCO	Â

Signatures

/s/ Avery W. Catlin, attorney-in-fact
07/01/2015
Date

Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option became exercisable as to 25% of the shares on 6/1/2013. This option is currently vested as to 6,250 shares and the remaining shares vest quarterly (in equal amounts) over the subsequent 4 quarters.
- (2) The option became exercisable as to 25% of the shares on 7/1/2014. This option is currently vested as to 10,000 shares and the remaining shares vest quarterly (in equal amounts) over the subsequent 8 quarters.
- (3) The option became exercisable as to 25% of the shares on 6/4/2015. This option is currently vested as to 6,250 shares and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
- (4) The option becomes exercisable as to 25% of the shares on 6/10/2016 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.

Â

Remarks:

Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.